Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License ...

An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limited has successfully completed the FDA’s Project Optimus ...

Johns Hopkins scientists discovered a way to convert “immune-cold” tumors into “immune-hot” ones by activating key immune ...

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to ...

Immutep Ltd ( ($AU:IMM) ) just unveiled an announcement. Immutep Limited has announced a significant milestone in its TACTI-004 (KEYNOTE-F91) ...

As the Australian market experiences a slight pullback following a bullish surge, investors are keenly observing the ASX 200's movements amidst fluctuating global economic factors such as U.S.

Acute promyelocytic leukemia (APL) represents a paradigm of targeted therapy in hematologic malignancies. Once regarded as ...

Spontaneous regression is most commonly reported in neuroblastoma and leukemia. Case series link infection, transfusion, and ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...

AI Technology Group Inc. (OTCID: AIPG) (the “Company”) announced that it has filed an amended Form 10 with the Securities and ...